← FDA DRUG APPROVALS

FDA ANDA · ANDA077205

IRBESARTAN

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA077205
TYPE
ANDA
ORIGINAL APPROVAL
2012-11-14
LATEST ACTION
2026-07-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

IRBESARTANPrescription
IRBESARTAN 75MG · TABLET · ORAL
IRBESARTANPrescription
IRBESARTAN 150MG · TABLET · ORAL
IRBESARTANPrescription
IRBESARTAN 300MG · TABLET · ORAL

Approval history

2026-07-13Labeling · Supplement 2 · standardAP
2015-11-18Labeling · Supplement 1 · standardAP
2012-11-14OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →